Interleukin-4 in the treatment of AIDS-related Kaposi's sarcoma

Annals of Oncology

Volumn 8, Issue 1, 1997, Pages 79-83

  Tulpule, A ^a   Joshi, B ^b   DeGuzman, N ^a   Espina, B M ^a   Mocharnuk, R ^a   Prakash, O ^b   Templeton, D ^c   Levine, A M ^a   Gill, P S ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b OCHSNER MEDICAL CENTER   (United States)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

AIDS related Kaposi's sarcoma; interleukin 4

Indexed keywords

DIDANOSINE; INTERLEUKIN 4; VIRUS RNA; ZALCITABINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ANEMIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; EDEMA; FEVER; HEADACHE; HUMAN; KAPOSI SARCOMA; MALE; NEUTROPENIA; PRIORITY JOURNAL; SKIN CANCER; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0031054428     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008205424763     Document Type: Article

References (25)

1. Centers for Disease Control and Prevention: HIV/AIDS Surveillance Report. February 1993; 1-23.
2. Lane HC, Feinberg J, Davey V et al. Anti-retroviral effects of interferon-α in AIDS-associated Kaposi's sarcoma. Lancet 1988; 2: 1218-22.
3. Groopman JE, Scadden DT. Interferon therapy in Kaposi's sarcoma associated with the acquired immunodeficiency syndrome (AIDS). Ann Intern Med 1989; 100: 335-7.
4. Laubenstein LJ, Krigel RL, Odajnyk CM et al. Treatment of epidemic Kaposi's sarcoma with etoposide or a combination of doxorubicin, bleomycin, and vinblastine. J Clin Oncol 1984; 2: 1115-20.
5. Gill PS, Rarick MU, McCutchan JA et al. Systemic treatment of AIDS-related Kaposi's sarcoma: Results of a randomized trial. Am J Med 1991; 90: 427-33.
6. Kishimoto T. Factors affecting B-cell growth and differentiation. Annu Rev Immunol 1985; 3: 133-57.
7. Hu-Li J, Shevach EM, Nizuguchi J et al. B-cell stimulatory factor 1 (interleukin-4) is a potent costimulant for normal resting T-lymphocytes. J Exp Med 1987; 165: 157.
8. Mosmann TR, Bond NW, Coffman RL et al. T-cell and mast cell lines respond to B-cell stimulatory factor-1. Proc Natl Acad Sci USA 1986; 83: 5654.
9. Fernandez-Botran R, Krammer PH, Diamenstein T et al. B-cell stimulatory factor 1 (BSF-1) promotes growth of helper T-cell lines. J Exp Med 1986; 164: 580.
10. Tepper RI, Pattengale PK, Leder P. Murine interleukin-4 displays potent anti-tumor activity in vivo. Cell 1989; 57: 503-12.
11. Gill P, Puri RK. Interleukin-4 receptor (IL-4R) expression on AIDS-related Kaposi's sarcoma (AIDS-KS) cells and inhibition of tumor cell growth and cytokine production by IL-4. Proc AACR 1993; 34: a1121.
12. Gilleece MH, Scarffe JH. Ghosh A et al. Recombinant human interleukin-4 (IL-4) given as daily subcutaneous injections - a phase I dose toxicity trial. Br J Cancer 1992: 66; 204-10.
13. Prendiville J, Thatcher N, Lind M et al. Administered by the intravenous and subcutaneous routes in patients with advanced cancer - a phase I toxicity study and pharmacokinetic analysis. Eur J Cancer 1993: 29A; 1700-7.
14. Atkins MT, Vachino G, Tilg HJ et al. Phase I evaluation of thrice-daily intravenous bolus interleukin-4 in patients with refractory malignancy. J Clin Oncol 1992; 10: 1802-9.
15. Sosman JA, Fisher SG. Fefer C et al. A phase I trial of continuous infusion interleukin-4 (IL-4) alone and following interleukin-2 (IL-2) in cancer patients. Ann Oncol 1994; 5: 447-52.
16. Margolin K. Aronson, FM, Sznol M et al. Phase II studies of recombinant human interleukin-4 in advanced renal cancer and malignant melanoma. J Immunother with emphasis on Immunol 1994; 15: 147-53.
17. Puri RK, Siegal JP. Interleukin-4 and cancer therapy. Cancer Invest 1993; 11: 474-86.
18. Maher D, Boyd A, McKendrick J et al. Rapid response of B-cell malignancies induced by interleukin-4. Blood 1990; 76 (Suppl) 152a (Abstr).
19. Piatek M, Luk K-C, Williams B, Lifson JD. Quantitative competitive polymerase chain reaction for accurate quantitation of HIV DNA and RNA species. Biotechniques 1993; 14: 70-80.
20. Kazazi F, Mathijs JM, Chang J et al. Recombinant interleukin-4 stimulates human immunodeficiency virus production by infected monocytes and macrophages. J Gen Virol 1992; 73: 941-9.
21. Poli G, Kinter A, Justement JS et al. Tumor necrosis factor α functions in an autocrine manner in the induction of human immunodeficiency virus expression. Proc Natl Acad Sci USA 1990; 87: 782-5.
22. Poli G, Bressler P, Kitner A et al. Interleukin-6 induces human immunodeficiency virus espression in infected monocytic cells alone and in synergy with tumor necrosis factor α by transcriptional and post transciprtional mchanisms. J Exp Med 1990: 172: 151-8.
23. Hart PH, Vitti GF, Burgess DR et al. Potential antiinflammatory effects of interleukin-4: Suppression of human monocyte, tumor necrosis factor α, interleukin-1 and prostoglandin E2. Proc Natl Acad Sci (USA) 1989; 86: 3803.
24. Lee JD, Swisher SG, Minehart EH et al. Interleukin-4 down-regulates interleukin-6 production in human peripheral blood nonuclear cells. J Leukoc Biol 1990; 47: 475.
25. Clerici M, Hakin FT. Venzon DJ et al. Changes in interleukin-2 and interleukin-4 production in asymptomatic human immunodeficiency virus seropositive individuals. J Clin Invest 1993; 91: 759-65.